2022 / 06

Next Paper
DOI: 10.24075/brsmu.2022.064

ORIGINAL RESEARCH

Peculiarities of amino acid profile in monocytes in breast cancer

Novoselova AV1, Yushina MN1, Patysheva MR2,3, Prostakishina EA1, Bragina OD2, Garbukov EYu2, Kzhyshkowska JG3,4,5,6
About authors

1 Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Moscow, Russia

2 Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, Russia

3 Tomsk National State University, Tomsk, Russia

4 Siberian State Medical University, Tomsk, Russia

5 Institute of Transfusion Medicine and Immunology, Faculty of Medicine Mannheim, University of Heidelberg, Heidelberg, Germany

6 German Red Cross Blood Service Baden-Württemberg-Hesse, Mannheim, Germany

Correspondence should be addressed: Anastasia V. Novoselova
Academik Oparin street, 4, Moscow, 117198, Russia; moc.liamg@hciveknarfv

About paper

Funding: The study was financially supported by the Russian Federation represented by the Ministry of Science and Higher Education of the Russian Federation (agreement dated 29 September 2021 № 075-15-2021-1073 on the topic "Genetic and epigenetic editing of tumor cells and the microenvironment in order to block metastasis ").

Author contribution: Novoselova АV — material processing, monocyte amino acid profile analysis, statistical data processing, text editing; Yushina MN — material processing, text writing and editing; Patysheva MR — study concept and design, monocyte isolation; Prostakishina EA — monocyte isolation; Bragina OD, Garbukov EY — patient selection, collection of biological material; Kzhyshkowska JG — study concept and design.

Compliance with ethical standards: the study is approved by the ethics committee of the Research Institute of Oncology under Tomsk National Research Medical Center (record No.10 dated 05 December 2019), was conducted in accordance with the standards of the ethics committee of V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, federal laws of the Russian Federation (Nos. 152, 323, etc.) and the 1964 Declaration of Helsinki with all subsequent additions and amendments regulating scientific research on biomaterials obtained from humans. All participants signed an informed consent to participate in the study.

Received: 2022-12-08 Accepted: 2022-12-22 Published online: 2022-12-28
|
  1. Kzhyshkowska J, Gudima A, Moganti K, Gratchev A, Orekhov A. Perspectives for Monocyte/Macrophage-Based Diagnostics of Chronic Inflammation. Transfus Med Hemotherapy. 2016; 43 (2): 66–77.
  2. Nikitina E, Larionova I, Choinzonov E, Kzhyshkowska J. Monocytes and macrophages as viral targets and reservoirs. Int J Mol Sci. 2018; 19 (9). DOI: 10.3390/ijms19092821.
  3. Patysheva M, Larionova I, Stakheyeva M, Grigoryeva E, Iamshchikov P, Tarabanovskaya N, et al. Effect of Early-Stage Human Breast Carcinoma on Monocyte Programming. Front Oncol. 2022; 11 (February): 1–12.
  4. Matuschik L, Riabov V, Schmuttermaier C, Sevastyanova T, Weiss C, Klüter H, et al. Hyperglycemia Induces Inflammatory Response of Human Macrophages to CD163-Mediated Scavenging of Hemoglobin-Haptoglobin Complexes. Int J Mol Sci. 2022; 23 (3): 1–19.
  5. Patysheva M, Frolova A, Larionova I, Afanas’ev S, Tarasova A, Cherdyntseva N, et al. Monocyte programming by cancer therapy. Front Immunol. 2022; 13 (October): 1–21.
  6. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011; 475 (7355): 222–5.
  7. Hanna RN, Cekic C, Sag D, Tacke R, Thomas GD, Nowyhed H, et al. Patrolling monocytes control tumor metastasis to the lung. Science (80- ). 2015; 350 (6263): 985–90.
  8. Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat Rev Immunol. 2011; 11 (11): 762–74.
  9. Engblom C, Pfirschke C, Pittet MJ. The role of myeloid cells in cancer therapies. Nat Rev Cancer. 2016; 16 (7): 447–62.
  10. Fox CJ, Hammerman PS, Thompson CB. Fuel feeds function: Energy metabolism and the T-cell response. Nat Rev Immunol. 2005; 5 (11): 844–52.
  11. Andrejeva G, Rathmell JC. Similarities and Distinctions of Cancer and Immune Metabolism in Inflammation and Tumors. Cell Metab. 2017; 26 (1): 49–70.
  12. Bauer DE, Harris MH, Plas DR, Lum JJ, Hammerman PS, Rathmell JC, et al. Cytokine stimulation of aerobic glycolysis in hematopoietic cells exceeds proliferative demand. FASEB J. 2004; 18 (11): 1303–5.
  13. Leone RD, Powell JD. Metabolism of immune cells in cancer. Nat Rev Cancer. 2020; 20 (9): 516–31.
  14. Schmidt DR, Patel3 R, Kirsch DG, Lewis5 CA, Heiden MG Vander, Locasale4 JW. Metabolomics in Cancer Research and Emerging Applications in Clinical Oncology. CA Cancer J Clin. 2021; 71 (4): 333–58.
  15. Odom JD, Sutton VR. Metabolomics in Clinical Practice: Improving Diagnosis and Informing Management. Clin Chem. 2021; 67 (12): 1606–17.
  16. Clish CB. Metabolomics: an emerging but powerful tool for precision medicine. Mol Case Stud. 2015; 1 (1): a000588.
  17. Wishart DS. Emerging applications of metabolomics in drug discovery and precision medicine. Nat Rev Drug Discov. 2016; 15 (7): 473–84.
  18. Viola A, Munari F, Sánchez-Rodríguez R, Scolaro T, Castegna A. The metabolic signature of macrophage responses. Front Immunol. 2019; 10 (JULY): 1–16.
  19. Schairer DO, Chouake JS, Nosanchuk JD, Friedman AJ. The potential of nitric oxide releasing therapies as antimicrobial agents. Virulence. 2012; 3 (3): 271–9.
  20. Van den Bossche J, Baardman J, Otto NA, van der Velden S, Neele AE, van den Berg SM, et al. Mitochondrial Dysfunction Prevents Repolarization of Inflammatory Macrophages. Cell Rep. 2016; 17 (3): 684–96.
  21. Qualls JE, Subramanian C, Rafi W, Smith AM, Defreitas AA, Shirey KA, et al. Sustained generation of nitric oxide and control of mycobacterial infection requires argininosuccinate synthase 1. Cell Host Microbe. 2012; 12 (3): 313–23.
  22. Kaprin AD, Starinskij VV, Petrova GV, redaktory. Zlokachestvennye novoobrazovaniya v Rossii v 2017 godu (zabolevaemost' i smertnost'). M.: MNIOI im. P. A. Gercena — filial FGBU «NMIC radiologii» Minzdrava Rossii, 2018; 250 s. Russian.
  23. Cassetta L, Pollard JW. Repolarizing macrophages improves breast cancer therapy. Cell Res. 2017; 27 (8): 963–4.
  24. Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C, et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med. 2009; 206 (6): 1327–37.
  25. De Sanctis F, Adamo A, Canè S, Ugel S. Targeting tumour-reprogrammed myeloid cells: the new battleground in cancer immunotherapy. Semin Immunopathol. 2022; (0123456789). DOI: 10.1007/s00281-022-00965-1.
  26. Nguyen PHD, Wasser M, Tan CT, Lim CJ, Lai HLH, Seow JJW, et al. Trajectory of immune evasion and cancer progression in hepatocellular carcinoma. Nat Commun. 2022; 13 (1): 1–13.
  27. Zhu Y, Li X, Wang L, Hong X, Yang J. Metabolic reprogramming and crosstalk of cancer-related fibroblasts and immune cells in the tumor microenvironment. Front Endocrinol (Lausanne). 2022; 13 (August): 1–26.
  28. Larionova I, Tuguzbaeva G, Ponomaryova A, Stakheyeva M, Cherdyntseva N, Pavlov V, et al. Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers. Front Oncol. 2020; 10 (October): 1–34.
  29. Larionova I, Cherdyntseva N, Liu T, Patysheva M, Rakina M, Kzhyshkowska J. Interaction of tumor-associated macrophages and cancer chemotherapy. Oncoimmunology. 2019; 8 (7): 1–15.
  30. Olingy CE, Dinh HQ, Hedrick CC. Monocyte heterogeneity and functions in cancer. J Leukoc Biol. 2019; 106 (2): 309–22.
  31. Pan S, Fan M, Liu Z, Li X, Wang H. Serine, glycine and one-carbon metabolism in cancer (Review). Int J Oncol. 2021; 58 (2): 158–70.
  32. Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity. 2005; 22 (5): 633–42.
  33. Munn BDH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T Cell Proliferation by Macrophage. 1999; 189 (9): 1363–72.
  34. Platten M, Wick W, Van Den Eynde BJ. Tryptophan catabolism in cancer: Beyond IDO and tryptophan depletion. Cancer Res. 2012; 72 (21): 5435–40.
  35. Moffett JR, Namboodiri MA. Tryptophan and the immune response. Immunol Cell Biol. 2003; 81 (4): 247–65.
  36. Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature. 2011; 478 (7368): 197–203.
  37. Stephens GL, Wang Q, Swerdlow B, Bhat G, Kolbeck R, Fung M. Kynurenine 3-monooxygenase mediates inhibition of Th17 differentiation via catabolism of endogenous aryl hydrocarbon receptor ligands. Eur J Immunol. 2013. 43 (7): 1727–34. DOI: 10.1002/eji.201242779.
  38. RE N, TA M. Dual Requirement of Walker Carcinosarcoma 256 in vitro for Asparagine and Glutamine. Science. 1956; 124 (3212): 124–5.
  39. Clavell LA, Gelber RD, Cohen HJ, Suzanne Hitchcock-Bryan RN, Cassady JR, Tarbel NJ, et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med. 1986; 315: 657–63.